Ordering
Available Variants5 mg
CHA.45236-5mg
Price
€96.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.45236-5mg | €96.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H10ClF3N2O3 |
|---|---|
| CAS Number | 202821-81-6 |
| Molecular Weight | 370.71 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H301,H413 |
| pcodes | P264 - P270 - P273 - P301 + P310 - P405 - P501 |
| Hazard Classifications | Acute Tox. 3 Oral - Aquatic Chronic 4 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
BMS-191011, also known by its CAS number 202821-81-6, is a potent and selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). This compound has been investigated for its potential therapeutic applications, particularly in the treatment of cancer and autoimmune diseases. By inhibiting DHODH, BMS-191011 disrupts the de novo pyrimidine biosynthesis pathway, which is essential for the proliferation of rapidly dividing cells, such as cancer cells and activated lymphocytes. The inhibition of this pathway can lead to the depletion of pyrimidine nucleotides, ultimately resulting in the suppression of cell growth and proliferation. As a result, BMS-191011 has shown promise as a potential therapeutic agent in preclinical studies, and its mechanism of action suggests that it may be useful in the treatment of a range of diseases characterized by abnormal cell growth and proliferation.
